154 related articles for article (PubMed ID: 3561171)
1. Central muscarinic control of the pattern of small intestinal motility in rats.
Fargeas MJ; Fioramonti J; Buéno L
Life Sci; 1987 Apr; 40(17):1709-15. PubMed ID: 3561171
[TBL] [Abstract][Full Text] [Related]
2. Effects of intracerebroventricular pirenzepine on muscarinic discriminations in rats.
Jung M; Perio A; Terranova JP; Worms P; Biziere K
Eur J Pharmacol; 1987 Jul; 139(1):111-6. PubMed ID: 3653237
[TBL] [Abstract][Full Text] [Related]
3. Role of muscarinic receptor subtypes in the regulation of migrating myoelectric complex in the dog.
Schiavone A; Sagrada A; Pagani F; Giachetti A
Gastroenterology; 1989 Jan; 96(1):116-21. PubMed ID: 2909418
[TBL] [Abstract][Full Text] [Related]
4. Muscarinic receptor subtypes and sexual behavior in female rats.
Dohanich GP; McMullan DM; Cada DA; Mangum KA
Pharmacol Biochem Behav; 1991 Jan; 38(1):115-24. PubMed ID: 1708147
[TBL] [Abstract][Full Text] [Related]
5. Clonazepam-induced intestinal motor disturbances are linked to central nervous system release of cholecystokinin in rats.
Bonnafous C; Martinez J; Fargeas MJ; Buéno L
Eur J Pharmacol; 1993 Jun; 237(2-3):237-42. PubMed ID: 8396038
[TBL] [Abstract][Full Text] [Related]
6. Role of hypothalamic cholecystokinin octapeptide in the colonic motor response to a meal in rats.
Liberge M; Arruebo MP; Bueno L
Gastroenterology; 1991 Feb; 100(2):441-9. PubMed ID: 1985040
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of antimuscarinic agents on intestinal motility in the conscious dog.
de Ponti F; Einaudi A; Cosentino M; D'Angelo L; Lecchini S; Frigo GM; Crema A
J Pharmacol Exp Ther; 1993 Feb; 264(2):789-94. PubMed ID: 8437127
[TBL] [Abstract][Full Text] [Related]
8. Peripheral and central administration of exogenous urocortin 1 disrupts the fasted motility pattern of the small intestine in rats via the corticotrophin releasing factor receptor 2 and a cholinergic mechanism.
Yin Y; Dong L; Yin D
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e79-87. PubMed ID: 17944898
[TBL] [Abstract][Full Text] [Related]
9. Central oxotremorine antagonist properties of pirenzepine.
Witkin JM; Alvarado-Garcia R; Perez LA; Witkin KM
Life Sci; 1988; 42(24):2467-73. PubMed ID: 3374266
[TBL] [Abstract][Full Text] [Related]
10. Central muscarinic M2 cholinoceptors involved in cholinergic hypertension.
Ozkutlu U; Onat F; Aslan AN; Oktay S
Eur J Pharmacol; 1993 Dec; 250(3):349-54. PubMed ID: 8112394
[TBL] [Abstract][Full Text] [Related]
11. The rebound excitation triggered by anticholinergic drugs from ovine pyloric antrum, small bowel and gallbladder.
Romański KW
J Physiol Pharmacol; 2003 Mar; 54(1):121-33. PubMed ID: 12674224
[TBL] [Abstract][Full Text] [Related]
12. On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex.
Forray C; el-Fakahany EE
Mol Pharmacol; 1990 Jun; 37(6):893-902. PubMed ID: 2163015
[TBL] [Abstract][Full Text] [Related]
13. Muscarinic receptor agonist-mediated modulation of neuronal activity in rat cerebral cortex.
Lin Y; Phillis JW
Eur J Pharmacol; 1991 Jul; 200(1):45-52. PubMed ID: 1722754
[TBL] [Abstract][Full Text] [Related]
14. Cholinergic antagonists and REM sleep generation.
Velazquez-Moctezuma J; Shalauta M; Gillin JC; Shiromani PJ
Brain Res; 1991 Mar; 543(1):175-9. PubMed ID: 2054672
[TBL] [Abstract][Full Text] [Related]
15. Central alpha 2-adrenergic control of the pattern of small intestinal motility in rats.
Fargeas MJ; Fioramonti J; Bueno L
Gastroenterology; 1986 Dec; 91(6):1470-5. PubMed ID: 3021557
[TBL] [Abstract][Full Text] [Related]
16. Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase.
Gil DW; Wolfe BB
J Pharmacol Exp Ther; 1985 Mar; 232(3):608-16. PubMed ID: 2579230
[TBL] [Abstract][Full Text] [Related]
17. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine.
Flynn DD; Mash DC
J Pharmacol Exp Ther; 1989 Aug; 250(2):573-81. PubMed ID: 2760841
[TBL] [Abstract][Full Text] [Related]
18. Antimuscarinic potency and functional selectivity of oxotremorine analogs at muscarinic receptor subtypes in the rat.
Vargas HM; Ringdahl B
Life Sci; 1990; 47(22):2065-73. PubMed ID: 1703260
[TBL] [Abstract][Full Text] [Related]
19. M-1 and M-2 muscarinic receptor-mediated inhibition of dopamine-sensitive adenylate cyclase in rat neostriatum: a permissive role for D-2 dopamine receptors.
Schoffelmeer AN; Hogenboom F; Mulder AH
J Pharmacol Exp Ther; 1988 May; 245(2):658-63. PubMed ID: 2452877
[TBL] [Abstract][Full Text] [Related]
20. Central pressor effects induced by muscarinic receptor agonists: evidence for a predominant role of the M2 receptor subtype.
Pazos A; Wiederhold KH; Palacios JM
Eur J Pharmacol; 1986 Jun; 125(1):63-70. PubMed ID: 3732392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
